MRNA
Marina Biotech, Inc.
Other OTC
People also watch:RXIICYCCPARDOPXAGNVC
0.140.00 (1.89%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close0.14
Open0.14
Bid0.00 x
Ask0.00 x
52wk Range0.11 - 0.52
Day's Range0.14 - 0.14
Volume20,315
Avg Vol (3m)159,109
As of 1:31 PM EDT. Market closed.
  • Marina Biotech, Inc. Earnings Q3, 2015
    Capital Cube8 months ago

    Marina Biotech, Inc. Earnings Q3, 2015

    Click here to see latest analysisMarina Biotech, Inc. reports financial results for the quarter ended September 30, 2015.We analyze the earnings along side the following peers of Marina Biotech, Inc. – Regulus Therapeutics Inc., Merck & Co., Inc., Athersys, Inc., Alnylam Pharmaceuticals, Inc, Johnson & Johnson, Monsanto Company, Novartis AG Sponsored ADR, Flamel Technologies SA […] (Read more...) The post Marina Biotech, Inc. Earnings Q3, 2015 appeared first on CapitalCube.

  • Marina Biotech, Inc. – Value Analysis (US OTC:MRNA) : November 3, 2015
    Capital Cube9 months ago

    Marina Biotech, Inc. – Value Analysis (US OTC:MRNA) : November 3, 2015

    Capitalcube gives Marina Biotech, Inc. a score of 38.Our analysis is based on comparing Marina Biotech, Inc. with the following peers – Regulus Therapeutics Inc., Merck & Co., Inc., Athersys, Inc., Alnylam Pharmaceuticals, Inc, Johnson & Johnson, Monsanto Company, Arrowhead Research Corporation, Novartis AG Sponsored ADR, Flamel Technologies SA Sponsored ADR and Dicerna Pharmaceuticals, Inc. […] (Read more...) The post Marina Biotech, Inc. – Value Analysis (US OTC:MRNA) : November 3, 2015 appeared first on CapitalCube.